Site-Specific Suppression of Cell-Mediated Immunity By Cyclosporine

Site-Specific Suppression of Cell-Mediated Immunity By Cyclosporine

In this study, it was demonstrated that site-specific suppression of T-cell-mediated immune responsiveness could indeed be achieved by topical application of cyclosporine. Evidence for site-specific immune suppression was obtained from a dual skin allograft model in rats. These animals were given an...

Full description

Saved in:
Bibliographic Details
Published in:Journal of investigative dermatology Vol. 94; no. 5; pp. 644 - 648
Main Authors: Black, Kirby S., Nguyen, Danh K., Proctor, Collette M., Patel, Mayuri P., Hewitt, Charles W.
Format: Journal Article
Language:English
Published: Danvers, MA Elsevier Inc 01-05-1990
Nature Publishing
Subjects:
Animals
Biological and medical sciences
Cyclosporins
Cyclosporins - pharmacology
Dermatitis
Dermatology
DNA biosynthesis
Graft Rejection
Immune response
Immune Tolerance - drug effects
Immunity (cell-mediated)
Immunity, Cellular - drug effects
Immunomodulators
Inflammatory diseases
Lymphocytes
Lymphocytes T
Medical sciences
Pharmacology. Drug treatments
Psoriasis
Rats
Rats, Inbred Lew
Rats, Inbred Strains
Skin
Skin diseases
Skin Transplantation - immunology
Topical application
Cellular immunity
Immune response
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this study, it was demonstrated that site-specific suppression of T-cell-mediated immune responsiveness could indeed be achieved by topical application of cyclosporine. Evidence for site-specific immune suppression was obtained from a dual skin allograft model in rats. These animals were given an initial 10-d systemic treatment of CsA. Subsequently, one allograft was treated with topical CsA and the other was treated with the vehicle alone. Anti-inflammatory efficacy and prolonged skin allograft survival were observed both grossly and histopathologically in the presence of topically administered CsA, while contralateral vehicle-treated control grafts underwent vigorous rejection. Systemic lymphocyte DNA synthesis following Con-A and PHA stimulation was normal to elevated. Therefore, systemic T-cell-mediated immunity appeared unaffected or possibly activated even with concomitant topical GsA treatment. CsA levels were low systemically, and showed relative site-specificity in terms of tissue concentration. In conclusion, this study indicates that topical CsA is capable of locally suppressing a strong T-cell-mediated immune response after an initial short-term systemic dose of GsA. Furthermore, certain putative autoimmune and inflammatory diseases of the skin, such as psoriasis and eczematous dermatitis, which may share common mechanisms of action compared to skin allograft rejection should likewise benefit from topical CsA treatment.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0022-202X
1523-1747
DOI:10.1111/1523-1747.ep12876218